Nerve Degeneration

Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification

3 months ago talkbio0Tagged Alzheimer 's disease, Biogen, diversification, Immunology, Nerve Degeneration, Neuroscience discipline, Research Strategy

Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration

Booster Therapeutics Launches with $15 Million Funding to Pioneer Proteasome Activator Therapies for Neurodegenerative Diseases

7 months ago talkbio0Tagged DCLRE1B gene, Health Ventures, Holdings, multicatalytic endopeptidase complex, Nerve Degeneration, Neurodegenerative Disorders, Proteasome Activator Therapies, Protein Degradation, Metabolic

Proteasome activator therapies, Neurodegenerative diseases, Booster Therapeutics, Novo Holdings, Apollo Health Ventures, 20S proteasome, Protein degradation, Neurodegeneration

Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy

7 months ago talkbio0Tagged Biogen, Clinical Trials, DEVOTE, Dose Regimen, High, Improvement, Motor function (observable entity), Nerve Degeneration, nusinersen, Spinal Muscular Atrophy, Spinraza

Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction

Eisai Partners with SEED Therapeutics for $1.5 Billion Biobucks Deal in Neurodegeneration and Oncology

9 months ago talkbio0Tagged biobucks, Eisai, molecular glue degraders, Neoplasms, Nerve Degeneration, Plant seeds

Eisai, SEED Therapeutics, biobucks deal, neurodegeneration, oncology, molecular glue degraders

Anavex’s New Analysis of Alzheimer’s Pill Shows Mixed Results

9 months ago talkbio0Tagged Alzheimer 's disease, amyloid-beta, Anavex, Blarcamesine, Cerebral atrophy, EMA Approval, Mental deterioration, Nerve Degeneration, Phase IIb/III trial, Treatment Effectiveness

Anavex, Alzheimer’s disease, blarcamesine, Phase IIb/III trial, clinical efficacy, neurodegeneration, cognitive decline, amyloid-beta, brain atrophy, EMA approval.